CellCentric
Developer of p300/CBP small-molecule inhibitor drug to treat cancer.
14
Funding Rounds
$243.5m
Money raised
Funding
Funding series
Funding Series Analysis
The company CellCentric has raised a total of $172m in funding over 14 rounds.
Key Insights:
- CellCentric Series C Round, May 2025: $120m
- CellCentric , May 2018: $26m
- Cellcentric Limited , May 2018: $26m
- CellCentric Venture round, October 2020: $33m
- CellCentric Venture round, May 2018: $26m
- CellCentric Venture round, June 2013: $5.97m
- CellCentric Grant (money), May 2010: $600.72k
- CellCentric Venture round, October 2007: $4.3m
- CellCentric Venture round, July 2006: $1.67m
CellCentric Series C Round, May 2025
$120m
CellCentric , May 2018
$26m
Cellcentric Limited , May 2018
$26m
CellCentric Venture round, October 2020
$33m
CellCentric Venture round, May 2018
$26m
CellCentric Venture round, June 2013
$5.97m
CellCentric Grant (money), May 2010
$600.72k
CellCentric Venture round, October 2007
$4.3m
CellCentric Venture round, July 2006
$1.67m
Industries
CellCentric is active in the following industries: